CERo Therapeutics Announces Receipt of Nasdaq Panel Determination

Trading of the Company’s shares of common stock on Nasdaq will be suspended at the open of trading on October 31

CERo plans to appeal the Panel determination, seek trading of its shares on the OTC Markets and continue clinical operations

Read more at globenewswire.com